





Instructions for use GABA ELISA







Table of contents

1.	Introduction	3
1.1	Intended use and principle of the test	3
1.2	Background	3
2.	Procedural cautions, guidelines, warnings and limitations	3
2.1	Procedural cautions, guidelines and warnings	3
2.2	Limitations	4
2.2.1	Interfering substances and proper handling of specimens	4
2.2.2	Drug and food interferences	4
2.2.3	High-Dose-Hook effect	4
3.	Storage and stability	4
4.	Materials	4
4.1	Contents of the kit	4
4.2	Calibration and Controls	6
4.3	Additional materials required but not provided in the kit	6
4.4	Additional equipment required but not provided in the kit	6
5.	Sample collection, handling and storage	6
6.	Test procedure	7
6.1	Preparation of reagents and further notes	7
6.2	Preparation of samples	7
6.3	Preparation of samples (75 – 7,500 ng/ml) – Extraction	8
6.4	Derivatization	8
6.5	GABA ELISA	8
6.6	Preparation of samples (25 - 5,500 ng/ml) - Extraction	9
6.7	Derivatization	9
6.8	GABA ELISA	9
7.	Calculation of results	9
7.1	Typical standard curve	10
8.	Control samples	10
9.	Assay characteristics	10
9.1	Performance data	10
9.2	Metrological Traceability	11
10.	References/Literature	12
11.	Changes	12

Version: 18.0-r *Effective: 2024-09-27* **2 / 12**

1. Introduction

1.1 Intended use and principle of the test

Enzyme Immunoassay for the quantitative determination of gamma-aminobutyric acid (GABA) in urine and various biological samples.

After extraction and derivatization gamma-aminobutyric acid (GABA) is quantitatively determined by ELISA.

The subsequent competitive ELISA uses the microtiter plate format. The antigen is bound to the solid phase of the microtiter plate. The derivatized analyte concentrations of the standards, controls and samples compete with the solid phase bound analytes for a fixed number of antibody binding sites. After the system is in equilibrium, free antigen and free antigen-antibody complexes are removed by washing. The antibody bound to the solid phase is detected by an anti-rabbit IgG-peroxidase conjugate using TMB as a substrate resulting in a colour reaction. The reaction is monitored at a wavelength of 450 nm.

Quantification of unknown samples is achieved by comparing their absorbance with a reference curve prepared with known standard concentrations. Manual processing of the ELISA is recommended. The use of automatic laboratory equipment is the responsibility of the user.

This product is not intended to clinical diagnoses.

1.2 Background

GABA (γ -aminobutyric acid) is one of the most important inhibitory neurotransmitter in the central nervous system (CNS). GABA operates through interneurones by the inhibition of the release of excitatory neurotransmitters. In the CNS GABA is synthesized from L-glutamic acid which is an excitatory neurotransmitter.

2. Procedural cautions, guidelines, warnings and limitations

2.1 Procedural cautions, guidelines and warnings

- (1) This kit is intended for professional use only. Users should have a thorough understanding of this protocol for the successful use of this kit. Only the test instruction provided with the kit is valid and must be used to run the assay. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
- (2) The principles of Good Laboratory Practice (GLP) must be followed.
- (3) In order to reduce exposure to potentially harmful substances, wear lab coats, disposable protective gloves and protective glasses where necessary.
- (4) All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. For dilution or reconstitution purposes, use deionized, distilled, or ultra-pure water. Avoid repeated freezing and thawing of reagents and specimens.
- (5) The microplate contains snap-off strips. Unused wells must be stored at 2 8 °C in the sealed foil pouch with desiccant and used in the frame provided. Microtiter strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up.
- (6) Duplicate determination of sample is highly recommended.
- (7) Once the test has been started, all steps should be completed without interruption. Make sure that the required reagents, materials, and devices are prepared for use at the appropriate time.
- (8) Incubation times do influence the results. All wells should be handled in the same order and time intervals.
- (9) To avoid cross-contamination of reagents, use new disposable pipette tips for dispensing each reagent, sample, standard and control.
- (10) A standard curve must be established for each run.
- (11) The controls should be included in each run and fall within established confidence limits. The confidence limits are listed in the QC-Report provided with the kit.
- (12) Do not mix kit components with different lot numbers within a test and do not use reagents beyond expiry date as shown on the kit labels.
- (13) Avoid contact with Stop Solution containing 0.25 M H₂SO₄. It may cause skin irritation and burns. In case of contact with eyes or skin, rinse off immediately with water.
- (14) TMB substrate has an irritant effect on skin and mucosa. In case of possible contact, wash eyes with an abundant volume of water and skin with soap and abundant water. Rinse contaminated items before reuse.
- (15) For information about hazardous substances included in the kit please refer to Safety Data Sheet (SDS). The Safety Data Sheet for this product is made available directly on the website of the manufacturer or upon request.
- (16) Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.
- (17) In case of any severe damage to the test kit or components, the manufacturer has to be informed in writing, at the latest, one week after receiving the kit. Severely damaged single components must not be used for a test run. They must be stored properly until the manufacturer decides what to do with them. If it is decided that they are no longer suitable for measurements, they must be disposed of in accordance with national regulations.

Version: 18.0-r Effective: 2024-09-27 3 / 12

2.2 Limitations

Any inappropriate handling of samples or modification of this test might influence the results.

2.2.1 Interfering substances and proper handling of specimens

Avoid excess of acid: excess of acid might exceed the buffer capacity of the dilution buffer. A **pH of 3.0** during the extraction is mandatory.

Hrine

Please note the sample preparation stabilization of the urine sample! It cannot be excluded that high acid concentrations lead to incorrect results. Up to $20 \mu l 6 N HCl per 1 ml urine no influence on the results was observed.$

2.2.2 Drug and food interferences

It is recommended to forgo food supplements which might influence GABA levels (lemon balm, velerian, vitamin B6, L-theanine and kava) 24 hours before urine sampling.

Furthermore, additional diets before urine sampling are not described in the literature.

In case of unusual GABA levels it is recommended to check if these are caused by interaction of the above listed substances.

2.2.3 High-Dose-Hook effect

No hook effect was observed in this test.

3. Storage and stability

Store kit and reagents at 2-8 °C until expiration date. Do not use kit and components beyond the expiry date indicated on the kit labels. Once opened, the reagents are stable for 2 months when stored at 2-8 °C. Reconstituted Equalizing Reagent which is not used immediately has to be stored in aliquots for max. 2 months at <-15 °C and may be thawed only once. Once the resealable pouch of the ELISA plate has been opened, care should be taken to close it tightly again including the desiccant.

4. Materials

4.1 Contents of the kit

BA D-0033	Ш 48	Macrotiter Plate - ready to use	
Content:	2 x 48 well plate, em	pty, in a resealable pouch	
BA D-0090	FOILS	Adhesive Foil – ready to use	
Content:	Adhesive foils in a re	sealable pouch	
Number:	3 x 4 foils		
BA E-0030	WASH-CONC 50x	Wash Buffer Concentrate – concentrated 50x	
Content:	Buffer with a non-ion	ic detergent and physiological pH	
Volume:	1 x 20 ml/vial, purple	e cap	
BA E-0040	CONJUGATE	Enzyme Conjugate – ready to use	
Content:	Goat anti-rabbit imm	unoglobulins conjugated with peroxidase	
Volume:	1 x 12 ml/vial, red ca	p	
Description:	Species is goat		
BA E-0055	SUBSTRATE	Substrate – ready to use	
Content:	Chromogenic substra hydrogen peroxide	Chromogenic substrate containing 3,3',5,5'-tetramethylbenzidine, substrate buffer and hydrogen peroxide	
Volume:	1 x 12 ml/vial, black	сар	
BA E-0080	STOP-SOLN	Stop Solution – ready to use	
Content:	0.25 M sulfuric acid		
Volume:	1 x 12 ml/vial, grey o	сар	

Version: 18.0-r Effective: 2024-09-27 4 / 12

BA E-2413 ASSAY-BUFF Assay Buffer – ready to use

Content: Buffer with alkaline pH
Volume: 1 x 20 ml/vial, yellow cap

Hazard pictograms:



GHS08 GHS07

Signal word: Danger Hazardous Boric acid

ingredients:

H360FD May damage fertility. Suspected of damaging the unborn child.

statements:

Hazard

Precautionary P201 Obtain special instructions before use.

statements: P280 Wear protective gloves, protective clothing, eye protection, face protection.

P308+P313 IF exposed or concerned: Get medical advice/attention.

P501 Dispose of contents/container to an authorised waste collection point.

Additional statements:

Restricted to professional users.

BA E-2428 EQUA-REAG Equalizing Reagent – lyophilized

Content: Lyophilized protein
Volume: 1 vial, brown cap
Description: Species is bovine

BA E-2442 EXTRACT-PLATE 48 Extraction Plate – ready to use

Content: 2 x 48 well plate, precoated with cation exchanger in a resealable pouch

D-REAGENT D-Reagent – ready to use

Content: Crosslinking agent in dimethylsulfoxide

Volume: 1 x 3 ml/vial, white cap

Hazard pictograms:

(!)

GHS07

Signal word: Warning

Hazardous Glutaraldehyde

ingredients:

Gracuitation, ac

statements:

Hazard

H317 May cause an allergic skin reaction.

Precautionary statements:

P261 Avoid breathing mist/vapours/spray. P280 Wear protective gloves.

P333+P313 If skin irritation or rash occurs: Get medical advice/attention. P501 Dispose of contents/container to an authorised waste collection point.

BA E-2458 Q-BUFFER Q-Buffer – ready to use

Content: TRIS buffer

Volume: 1 x 20 ml/vial, white cap

BA E-2510 AS GABA Antiserum – ready to use

Content: Rabbit anti-GABA antibody in buffer with proteins and non-mercury preservative, blue

coloured

Volume: 1 x 6 ml/vial, blue cap

Description: Species of antibody is rabbit, species of protein in buffer is bovine

Content: 1 x 96 wells (12x8) antigen precoated microwell plate in a resealable foil pouch with

desiccant

BA E-2541 ELUTION-BUFF Elution Buffer – ready to use

Content: Buffer with citric acid
Volume: 1 x 20 ml/vial, green cap

Version: 18.0-r *Effective: 2024-09-27* **5 / 12**

BA E-2560 DILUENT Diluent – ready to use

Content: Buffer with acidic pH Volume: 2 x 20 ml/vial, blue cap

Hazard pictograms:

(!)

GHS07

Signal word: Warning

BA E-2561 I-BUFFER I-Buffer – concentrated

Content: Buffer with non-ionic detergent and non-mercury preservative

Volume: 1 x 4 ml/vial, red cap

BA E-2787 NAOH NaOH – ready to use

Content: Sodium hydroxide solution Volume: 1 x 2 ml/vial, purple cap

Hazard

pictograms:

(!)

GHS07

Signal word: Warning

4.2 Calibration and Controls

Standards and Controls - ready to use

Cat. no.	Component	Colour/Cap	Concentration [ng/ml]	Concentration [nmol/l]	Volume/ Vial
BA E-2501	STANDARD A	white	0	0	4 ml
BA E-2502	STANDARD B	yellow	75	727	4 ml
BA E-2503	STANDARD C	orange	250	2,425	4 ml
BA E-2504	STANDARD D	blue	750	7,275	4 ml
BA E-2505	STANDARD E	grey	2,500	24,250	4 ml
BA E-2506	STANDARD F	black	7,500	72,750	4 ml
BA E-2551	CONTROL 1	green	Refer to QC-Report fo	or expected value and	4 ml
BA E-2552	CONTROL 2	red	acceptable range.		4 ml
	04045 / 17		. 413		

Conversion: GABA $[ng/ml] \times 9.7 = GABA [nmol/l]$

Content: Acidic buffer with non-mercury preservative, spiked with defined quantity of GABA

4.3 Additional materials required but not provided in the kit

- Water (deionized, distilled, or ultra-pure)
- Absorbent material (paper towel)

4.4 Additional equipment required but not provided in the kit

- Calibrated precision pipettes to dispense volumes between 10 500 μl; 12.5 ml
- Microtiter plate washing device (manual, semi-automated or automated)
- $-\,$ ELISA reader capable of reading absorbance at 450 nm and if possible 620 $-\,$ 650 nm
- Microtiter plate shaker (shaking amplitude 3 mm; approx. 600 rpm)
- Vortex mixer

Sample collection, handling and storage

Various biological samples can be used with this assay. The validation procedure was done for human urine samples.

Urine

Spontaneous urine (second morning urine) stabilized with 10 μ I 6 M HCl per 1 ml of urine sample can be used. The measurement results are related to the creatinine content of the sample.

Storage: up to 6 hours (18 – 25 °C); up to 14 days (2 – 8 °C); up to 6 months (< -15 °C).

Repeated freezing and thawing should be avoided. Avoid exposure to direct sunlight.

Version: 18.0-r *Effective: 2024-09-27* **6 / 12**

6. Test procedure

Allow all reagents and samples to reach room temperature and mix thoroughly by gentle inversion before use. Number the Extraction Plate, Macrotiter Plate and microwell plates (Microtiter Strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up). Duplicate determinations are recommended. The binding of the antisera and of the enzyme conjugate and the activity of the enzyme are temperature dependent. The higher the temperature, the higher the absorption values will be. Varying incubation times will have similar influences on the absorbance. The optimal temperature during the enzyme immunoassay is between 20 - 25 °C. If the product is prepared in parts, unused wells in Extraction and Macrotiter Plates should be covered to avoid contamination. After preparation, the used wells must be labelled to prevent double use.

During the overnight incubation at 2 - 8 °C with the antiserum, the temperature should be uniform all over the ELISA plate to avoid any drift and edge-effect.

The use of a microtiter plate shaker with the following specifications is mandatory: shaking amplitude 3 mm; approx. 600 rpm. Shaking with differing settings might influence the results.

6.1 Preparation of reagents and further notes

Wash Buffer

Dilute the 20 ml Wash Buffer Concentrate WASH-CONC 50X with water to a final volume of 1000 ml.

Storage: 2 months at 2 - 8 °C

Equalizing Reagent

Reconstitute the **EQUA-REAG** with **12.5 ml** of **ASSAY-BUFF**.

Reconstituted Equalizing Reagent which is not used immediately has to be stored in aliquots for max. 2 months at < -15 °C and may be thawed only once.

I-Buffer

Dilute the 4 ml **I-BUFFER** with water (deionized, distilled, or ultra-pure) to a final volume of 400 ml.

Storage: 2 months at 2 - 8 °C

D-Reagent

The **D-REAGENT** has a freezing point of 18.5 °C. Make sure that the **D-REAGENT** has reached room temperature and forms a homogeneous, crystal-free solution.

GABA Microtiter Strips

In rare cases residues of the blocking and stabilizing reagent can be seen in the wells as small, white dots or lines. These residues do not influence the quality of the product.

Extraction Plate

In rare cases residues of the cation exchanger can be seen in the wells as small, black dots or lines. These residues do not influence the quality of the product.

6.2 Preparation of samples

The GABA ELISA is a flexible test system for various biological sample types and volumes. It is not possible to give a general advice how to prepare the samples. However, the following basics should help the researcher to adapt the protocol to his specific needs:

For the determination of samples in a range **between 25 – 2,500 ng/ml**, standards and controls should always be **diluted 1:3** with water [e.g. 100 µl standard + 200 µl water (deionized, distilled, or ultra-pure)]. This predilution of the standards has to be taken into account in the calculation of results. The standards are diluted to make sure that the samples fall into the linear part of the standard curve. **Do not dilute samples**!

⚠ For the determination of samples in a range between 75 – 7,500 ng/ml, do not dilute standards, controls or samples.

- Avoid excess of acid: excess of acid might exceed the buffer capacity of the dilution buffer. A **pH of 3.0** during the extraction is mandatory.
- It is advisable to perform a **Proof of Principle** to determine the recovery of GABA from the samples. Prepare a stock solution of GABA. Add small amounts (to change the native sample matrix as less as possible) of the stock solutions to the sample matrix and check the recovery.
- Samples found with concentrations higher than the highest standard (Standard F) should be diluted accordingly with water (deionized, distilled, or ultra-pure) and have to be re-assayed.

If you need any support in establishing a protocol for your specific purposes, do not hesitate to contact the manufacturer directly!

Version: 18.0-r Effective: 2024-09-27 7 / 12

6.3 Preparation of samples (75 - 7,500 ng/ml) - Extraction

- 1. Pipette 100 μ I of the standards, controls and samples into the appropriate wells of the EXTRACT-PLATE 48.
- 2. Add 100 μl of the DILUENT to all wells. Cover plate with FOILS and incubate for 15 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- 3. **Discard** and blot dry by tapping the inverted plate on absorbent material. **Add 500 μl** of **I-Buffer** to each well and incubate for **5 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 4. Discard the wash and blot dry by tapping the inverted plate on absorbent material.
- 5. Pipette 150 μl of **ELUTION-BUFF** into the appropriate wells of the **EXTRACT-PLATE** 48. Cover plate with **FOILS** and incubate for 10 min at RT (20 25 °C) on a **shaker** (approx. 600 rpm).
- 6. Use 100 μ I for the subsequent derivatization!

6.4 Derivatization

- 1. Pipette 100 μl of the extracted standards, controls and samples into the appropriate wells of the Macrotiter Plate 48.
- **2.** Pipette **10** μ **I** of the **NAOH** into all wells.
- 3. Add 50 µl of the Equalizing Reagent (fresh prepared before assay) to all wells.
- 4. Incubate for 1 min on a shaker (approx. 600 rpm).
- 5. Pipette 10 μ I of the **D-REAGENT** into all wells.
- **6.** Cover plate with **FOILS** and incubate for **2 h** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 7. Pipette 100 µl Q-BUFFER into all wells.
- 8. Shake for 10 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- 9. Use 50 µl for the subsequent ELISA!

6.5 GABA ELISA

- 1. Pipette 50 μ I of the derivatized standards, controls and samples into the appropriate wells of the GABA Microtiter Strips \square GABA.
- 2. Pipette 50 μ I of the AS GABA into all wells and mix shortly.
- 3. Cover plate with **FOILS** and incubate for **15 20 h** (overnight) at **2 8 °C**.
- **4.** Remove the foil. Discard or aspirate the content of the wells. Wash the plate **3 x** by adding **300 μl** of **Wash Buffer, discarding** the content and **blotting dry each time** by tapping the inverted plate on absorbent material.
- 5. Pipette 100 μl of the CONJUGATE into all wells.
- 6. Incubate for 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- 7. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µl of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 8. Pipette 100 μl of the SUBSTRATE into all wells and incubate for 20 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- Avoid exposure to direct sunlight!
- **9.** Add **100 μl** of the **STOP-SOLN** to each well and shake the microtiter plate to ensure a homogeneous distribution of the solution.
- **10. Read** the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to **450 nm** (if available a reference wavelength between 620 nm and 650 nm is recommended).

Version: 18.0-r Effective: 2024-09-27 **8 / 12**

6.6 Preparation of samples (25 - 5,500 ng/ml) - Extraction

- 1. Pipette 300 μl of the diluted standards, controls and undiluted samples into the appropriate wells of the EXTRACT-PLATE 48.
- 2. Add **300 μl** of the **DILUENT** to all wells. Cover plate with **FOILS** and incubate for **30 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 3. Washing step (2 cycles):

Discard and blot dry by tapping the inverted plate on absorbent material. **Add 1 ml** of **I-Buffer** to each well and incubate the plate for **5 min** at **RT** (20 – 25 °C) on a **shaker** (approx. 600 rpm).

Discard and blot dry by tapping the inverted plate on absorbent material. **Add 1 ml** of **I-Buffer** to each well and incubate the plate for **5 min** at **RT** (20 – 25 °C) on a **shaker** (approx. 600 rpm).

- 4. **Discard** the wash and blot dry by tapping the inverted plate on absorbent material.
- 5. Pipette **150** μ l of **ELUTION-BUFF** into the appropriate wells of the **EXTRACT-PLATE 48**. Cover plate with **FOILS** and incubate for **10** min at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 6. Use 100 µl for the subsequent derivatization!

6.7 Derivatization

- 1. Pipette 100 μ I of the extracted standards, controls and samples into the appropriate wells of the Macrotiter Plate μ 48.
- 2. Pipette 10 μ I of the NAOH into all wells.
- 3. Add 50 µl of the Equalizing Reagent (fresh prepared before assay) to all wells.
- **4.** Incubate for **1 min** on a shaker (approx. 600 rpm).
- **5.** Pipette **10** μ I of the **D-REAGENT** into all wells.
- **6.** Cover plate with **FOILS** and incubate for **2 h** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 7. Pipette 100 µl Q-BUFFER into all wells.
- **8.** Shake for **10 min** at **RT** $(20 25 \, ^{\circ}\text{C})$ on a **shaker** (approx. 600 rpm).
- 9. Use 50 µl for the subsequent ELISA!

6.8 GABA ELISA

- 1. Pipette 50 μ I of the derivatized standards, controls and samples into the appropriate wells of the GABA Microtiter Strips \square GABA.
- 2. Pipette 50 μ I of the AS GABA into all wells and mix shortly.
- 3. Cover plate with FOILS and incubate for 15 20 h (overnight) at 2 8 °C.
- **4.** Remove the foil. Discard or aspirate the content of the wells. Wash the plate **3 x** by adding **300 μI** of **Wash Buffer, discarding** the content and **blotting dry each time** by tapping the inverted plate on absorbent material.
- 5. Pipette 100 μ I of the **CONJUGATE** into all wells.
- **6.** Incubate for **30 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 7. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µl of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 8. Pipette 100 μl of the SUBSTRATE into all wells and incubate for 20 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- Avoid exposure to direct sunlight!
- **9.** Add **100 μI** of the **STOP-SOLN** to each well and shake the microtiter plate to ensure a homogeneous distribution of the solution.
- **10. Read** the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to **450 nm** (if available a reference wavelength between 620 nm and 650 nm is recommended).

7. Calculation of results

GABA		BA
Measuring range	Test procedure 75 – 7,500 ng/ml	59.1 - 7,500 ng/ml
	Test procedure 25 – 2,500 ng/ml	25 - 2,500 ng/ml

The standard curve, which can be used to determine the concentration of the unknown samples, is obtained by plotting the absorbance readings (calculate the mean absorbance) of the standards (linear, y-axis) against the

Version: 18.0-r *Effective: 2024-09-27* **9 / 12**

corresponding standard concentrations (logarithmic, x-axis) using a concentration of 0.001 ng/ml for Standard A (this alignment is mandatory because of the logarithmic presentation of the data). Use non-linear regression for curve fitting (e.g. 4-parameter, marquardt).

This assay is a competitive assay. This means: the OD-values are decreasing with increasing concentrations of the analyte. OD-values found below the standard curve correspond to high concentrations of the analyte in the sample and have to be reported as being positive.

Samples and controls

The concentrations of the controls can be read directly from the standard curve.

The concentrations of the samples (Test procedure 75 – 7,500 ng/ml) can be read directly from the standard curve.

The concentrations of the samples (Test procedure 25 - 2,500 ng/ml) have to be divided by 3.


Samples found with concentrations higher than the highest standard (Standard F) should be diluted accordingly with water (deionized, distilled, or ultra-pure) and must be re-assayed. For the calculation of the concentrations this dilution factor has to be taken into account.

Conversion:

GABA $[ng/ml] \times 9.7 = GABA [nmol/l]$

7.1 Typical standard curve

 \triangle Example: Do not use for calculation!



8. Control samples

The confidence limits of the kit controls are indicated on the QC-Report.

9. Assay characteristics

Various biological samples can be used for GABA determination. The following data had been taken from the validation report and refer to human urine samples.

9.1 Performance data

Analytical Sensitivity		
	GABA	
Limit of Blank (LOB)	19.6 ng/ml	
Limit of Detection (LOD)	30.4 ng/ml	
Limit of Quantification (LOQ)	59.1 ng/ml	

Version: 18.0-r *Effective: 2024-09-27* **10 / 12**

Analytical Specificity (Cross Reactivity)			
Substance	Cross Reactivity [%]		
Substance	GABA		
3-Aminobutanoic acid	< 0.1		
L-(+)-2-Aminobutyric acid	< 0.1		
β-Alanine	0.8		
L-Aspartic acid	< 0.1		
(S)-(+)-Glutamine	< 0.1		
Glycine	< 0.1		
L-Glutamic acid	< 0.1		

Precision					
Intra-Assay			Inter-Assay		
Urine , n = 12			Urine , n = 13		
Sample	Mean ± SD [ng/ml]	CV [%]	Sample	Mean ± SD [ng/ml]	CV [%]
1	135 ± 32	23.7	1	205 ± 25.4	12.4
2	241 ± 30	12.6	2	426 ± 40	9.4
3	451 ± 41	9.2	3	944 ± 69	7.3
4	1,021 ± 56	5.5	4	2,763 ± 195	7.1
5	2,871 ± 200	7.2			
6	6,327 ± 322	5.1			

Lot-to-Lot			
	Sample	Mean ± SD [ng/ml]	CV [%]
GABA in urine (n = 3)	1	826 ± 82.5	10.0
	2	2,526 ± 129	5.1
GABA in artificial matrix (n = 3)	3	1,229 ± 21.0	1.7

Recovery was determined according to the CLSI standard EP 34 1st ed.

Recovery			
	Range [ng/ml]	Mean [%]	Range [%]
Urine	157 - 4,832	101	86 - 111

Linearity			
	Serial dilution up to	Mean [%]	Range [%]
Urine	1:64	110	98 - 123

9.2 Metrological Traceability

The values assigned to the standards and controls of the GABA ELISA are traceable to SI Units by weighing with quality-controlled analyte.

Standards and Controls	
	Uncertainty [%]
GABA	1.6

GABA ELISA		
Concentration [ng/ml]	Expanded Uncertainty [%] $k = 2^*$	
205	25.0	
426	19.1	
944	15.0	
2,763	14.6	

^{*} This defines an interval about the measured result that will include the true value with a probability of 95%.

Version: 18.0-r *Effective: 2024-09-27* **11 / 12**

10. References/Literature


- 1. Bieger, W.P., NeuroStress Guide. 2011.
- 2. Bustillo, J.R., *Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update.* Dialogues Clin Neurosci, 2013. **15**(3): p. 329-37.
- 3. Duman, R.S., G. Sanacora, and J.H. Krystal, *Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments*. Neuron, 2019. **102**(1): p. 75-90.
- 4. Femenía, T., et al., *Dysfunctional hippocampal activity affects emotion and cognition in mood disorders.* Brain Res, 2012. **1476**: p. 58-70.
- 5. Flasnoecker, M., *Reise aus dem Stress Körper, Geist und Psyche stärken*. 2015: W. Zuckschwerdt Verlag GmbH.
- 6. Frisardi, V., F. Panza, and A.A. Farooqui, *Late-life depression and Alzheimer's disease: the glutamatergic system inside of this mirror relationship.* Brain Res Rev, 2011. **67**(1-2): p. 344-55.
- 7. Gao, S.F. and A.M. Bao, *Corticotropin-releasing hormone, glutamate, and* γ -aminobutyric acid in depression. Neuroscientist, 2011. **17**(1): p. 124-44.
- 8. Harris, R.E. and D.J. Clauw, *Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy.* Neurosci Lett, 2012. **520**(2): p. 192-6.
- 9. Kendell, S.F., J.H. Krystal, and G. Sanacora, *GABA and glutamate systems as therapeutic targets in depression and mood disorders.* Expert Opin Ther Targets, 2005. **9**(1): p. 153-68.
- 10. Krystal, J.H., et al., *Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.* Mol Psychiatry, 2002. **7 Suppl 1**: p. S71-80.
- 11. Lener, M.S., et al., *Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.* Biol Psychiatry, 2017. **81**(10): p. 886-897.
- 12. Sanacora, G., G. Treccani, and M. Popoli, *Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.* Neuropharmacology, 2012. **62**(1): p. 63-77.
- 13. Strienz, J., *Nebennierenunterfunktion Stress stört die Hormonbalance*. 3 ed. 2019: W. Zuckschwerdtverlag München.

For updated literature or any other information please contact your local supplier.

11. Changes

Version	Release Date	Chapter	Change
17.0-r	2024-05-22	4.1	- Hazard labelling updated according to SDS
		7.2	- Typical standard curve updated
		9.1	- Lot-to-Lot added, Recovery updated
		9.2	- Chapter Metrological Traceability added
18.0-r	2024-09-27		- Symbols formated

Symbols:



Version: 18.0-r *Effective: 2024-09-27* **12 / 12**